NCT06413368View on ClinicalTrials.gov

Maralixibat in Patients With Cystic Fibrosis and Constipation, A Within-Subjects Pilot Study

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2027

Conditions
Constipation Chronic IdiopathicCystic Fibrosis
Interventions
DRUG

Maralixibat 9.5 MG/ML [Livmarli]

Within Study subjects receiving 2 weeks of treatment with Maralixibat 9.5 MG/ML \[Livmarli\] and compare to baseline treatment.

Trial Locations (1)

90027

Children's Hospital Los Angeles, Los Angeles

All Listed Sponsors
lead

Children's Hospital Los Angeles

OTHER

NCT06413368 - Maralixibat in Patients With Cystic Fibrosis and Constipation, A Within-Subjects Pilot Study | Biotech Hunter | Biotech Hunter